000888853 001__ 888853
000888853 005__ 20210118134516.0
000888853 0247_ $$2doi$$a10.3233/JPD-202117
000888853 0247_ $$2ISSN$$a1877-7171
000888853 0247_ $$2ISSN$$a1877-718X
000888853 0247_ $$2Handle$$a2128/26755
000888853 0247_ $$2pmid$$a32925097
000888853 0247_ $$2WOS$$aWOS:000587725300043
000888853 037__ $$aFZJ-2020-05267
000888853 082__ $$a610
000888853 1001_ $$0P:(DE-HGF)0$$aTang, Chris C.$$b0
000888853 245__ $$aHemispheric Network Expression in Parkinson’s Disease: Relationship to Dopaminergic Asymmetries
000888853 260__ $$aAmsterdam$$bIOS Press$$c2020
000888853 3367_ $$2DRIVER$$aarticle
000888853 3367_ $$2DataCite$$aOutput Types/Journal article
000888853 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1610547782_7608
000888853 3367_ $$2BibTeX$$aARTICLE
000888853 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000888853 3367_ $$00$$2EndNote$$aJournal Article
000888853 520__ $$aBackground:Parkinson’s disease (PD) is characterized by brain metabolic networks, specifically associated with motor and cognitive manifestations. Few studies have investigated network changes in cerebral hemispheres ipsilateral and contralateral to the clinically more affected body side.Objective:We examined hemispheric network abnormalities and their relationship to striatal dopaminergic deficits in PD patients at different stages.Methods:45 PD patients underwent dual-tracer positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) and 18F-fluorodopa (FDOPA) in a high-resolution PET scanner. In all patients, we computed expression levels for the PD-related motor/cognition metabolic patterns (PDRP/PDCP) as well as putamen/caudate FDOPA uptake values in both hemispheres. Resulting hemispheric measures in the PD group were compared with corresponding healthy control values and assessed across disease stages.Results:Hemispheric PDRP and PDCP expression was significantly elevated contralateral and ipsilateral to the more affected body side in patients with unilateral symptoms (H&Y 1: p < 0.01) and in patients with bilateral limb involvement (H&Y 2-3: p < 0.001; H&Y 4: p < 0.003). Elevations in pattern expression were symmetrical at all disease stages. By contrast, FDOPA uptake in the caudate and putamen was reduced bilaterally (p < 0.002), with lower values on both sides at more advanced disease stages. Hemispheric uptake was asymmetrical in both striatal regions, with lower contralateral values at all disease stages. The magnitude of hemispheric uptake asymmetry was smaller with more advanced disease, reflecting greater change ipsilaterally.Conclusion:Symmetrical network expression in PD represents bilateral functional effects unrelated to nigrostriatal dopaminergic asymmetries.
000888853 536__ $$0G:(DE-HGF)POF3-573$$a573 - Neuroimaging (POF3-573)$$cPOF3-573$$fPOF III$$x0
000888853 588__ $$aDataset connected to CrossRef
000888853 7001_ $$0P:(DE-HGF)0$$aHoltbernd, Florian$$b1
000888853 7001_ $$0P:(DE-HGF)0$$aMa, Yilong$$b2
000888853 7001_ $$0P:(DE-HGF)0$$aSpetsieris, Phoebe$$b3
000888853 7001_ $$0P:(DE-HGF)0$$aOh, Alice$$b4
000888853 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon R.$$b5$$ufzj
000888853 7001_ $$0P:(DE-HGF)0$$aTimmermann, Lars$$b6
000888853 7001_ $$0P:(DE-HGF)0$$aEggers, Carsten$$b7
000888853 7001_ $$0P:(DE-HGF)0$$aEidelberg, David$$b8$$eCorresponding author
000888853 773__ $$0PERI:(DE-600)2599550-9$$a10.3233/JPD-202117$$gVol. 10, no. 4, p. 1737 - 1749$$n4$$p1737 - 1749$$tJournal of Parkinson's Disease$$v10$$x1877-718X$$y2020
000888853 8564_ $$uhttps://juser.fz-juelich.de/record/888853/files/2020_Tang_Holtbernd_JofP_Postprint%20.pdf$$yOpenAccess
000888853 8564_ $$uhttps://juser.fz-juelich.de/record/888853/files/jpd_2020_10-4_jpd-10-4-jpd202117_jpd-10-jpd202117.pdf$$yRestricted
000888853 909CO $$ooai:juser.fz-juelich.de:888853$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000888853 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-HGF)0$$aForschungszentrum Jülich$$b1$$kFZJ
000888853 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b5$$kFZJ
000888853 9131_ $$0G:(DE-HGF)POF3-573$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vNeuroimaging$$x0
000888853 9141_ $$y2020
000888853 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-09-12
000888853 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-12
000888853 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-09-12
000888853 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ PARKINSON DIS : 2018$$d2020-09-12
000888853 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-09-12
000888853 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-09-12
000888853 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-09-12
000888853 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000888853 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-09-12
000888853 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-09-12
000888853 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-09-12
000888853 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x0
000888853 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x1
000888853 980__ $$ajournal
000888853 980__ $$aVDB
000888853 980__ $$aUNRESTRICTED
000888853 980__ $$aI:(DE-Juel1)INM-4-20090406
000888853 980__ $$aI:(DE-Juel1)INM-3-20090406
000888853 9801_ $$aFullTexts